I still remember a teacher in her late 40s who came in after two months of sleeping no more than three hours at a stretch. She had flushes so strong she kept a change of clothing in her car, her patience snapped without warning, and she was considering stepping away from work she loved. She did not want to “mess with hormones” because a friend had warned her about breast cancer. We talked through her history, her options, and started a low-dose transdermal estradiol patch with oral micronized progesterone. By her next visit she had slept through the night six times in two weeks. Two months later she was herself again. That is the promise of well-chosen hormone therapy. The details matter, and getting them right requires nuance.
Hormone replacement therapy, sometimes called hormone therapy or HRT therapy, refers to treatment with estrogen, progesterone, and sometimes testosterone to relieve symptoms of hormone deficiency and reduce certain long-term risks. In practice, that includes menopause hormone therapy for women, perimenopause hormone therapy during the transition years, and testosterone replacement therapy for men with true hypogonadism. You will also hear terms like bioidentical hormone therapy, compounded hormone therapy, hormone pellet therapy, and “hormone optimization therapy.” Not all of these are equivalent in safety or evidence. Good care separates marketing language from medical hormone therapy that has clear benefits for the right person, at the right dose, by the right route.
What HRT means, and what it does not
Estrogen therapy is the foundation of menopause treatment with hormones. It relieves hot flashes and night sweats, improves sleep, and treats genitourinary symptoms like vaginal dryness and pain with sex. Estrogen also preserves bone density and lowers fracture risk. Progesterone therapy is added for anyone with a uterus to protect the endometrium from excess estrogen stimulation. Men without sufficient testosterone may benefit from testosterone therapy, often called TRT therapy or a male TRT program, if symptoms and repeated blood tests confirm deficiency. Thyroid hormone therapy is its own domain, used for hypothyroidism, and is not part of traditional HRT for menopause or low testosterone, though some clinics market a combined endocrine hormone therapy program.
“Bioidentical” hormone replacement often simply means molecules that match human hormones, such as estradiol and micronized progesterone. Many FDA-approved products are bioidentical. Compounded hormones are made by specialized pharmacies, sometimes marketed as custom hormone therapy or personalized hormone therapy. Compounded options can be valuable when a standard dose or form is not available, but they are not FDA-approved, and potency can vary. For most people, starting with FDA-approved bioidentical hormone therapy is the safer path.
Who tends to benefit the most
The strongest and most consistent benefits of HRT appear in people with significant symptoms of hormone deficiency and in those who are early in menopause.
Women within 10 years of their final menstrual period, or younger than about 60, are the group most likely to see an excellent balance of benefits over risks. In surgical menopause, where both ovaries are removed, symptoms can be abrupt and severe. Estrogen replacement usually helps dramatically and also protects bone and possibly cardiovascular health when started promptly.
For perimenopause, symptoms can swing from week to week because ovarian output is erratic rather than absent. Low-dose transdermal estradiol can stabilize vasomotor symptoms and sleep, while cyclical or continuous progesterone smooths bleeding patterns. Some people in early perimenopause do better on a low-dose combined oral contraceptive for contraception, cycle control, and symptom relief, then transition to menopause HRT when periods have stopped for a full year.
Men with verified low testosterone, especially those with testicular or pituitary disease, can see improved sexual desire, morning erections, muscle mass, and bone density with testosterone replacement therapy. Improvements in energy and mood are variable and depend heavily on context like sleep apnea, thyroid status, iron deficiency, alcohol intake, and mood disorders.
Premature ovarian insufficiency is its own category. When the ovaries stop functioning before age 40, estrogen and progesterone replacement are recommended unless there is a contraindication, ideally continuing at least until the average age of natural menopause, to support bone, brain, and cardiovascular health.
Benefits you can count on, and where the evidence is thinner
Vasomotor symptoms relief is the headline benefit. Systemic estrogen reduces hot flashes and night sweats in most women by roughly 75 to 90 percent within weeks. Better sleep and a steadier mood often follow once the nocturnal thermostat calms down. Local vaginal estrogen, at a very low dose, treats dryness, burning, recurrent urinary tract infections, and pain with sex, with minimal systemic absorption. Many postmenopausal patients use local estrogen safely for years.
Bone health improves on therapy. Estrogen prevents postmenopausal bone loss and, in large trials, reduces fractures, including hip and vertebral fractures. If someone has already sustained a fragility fracture or meets criteria for osteoporosis, medications such as bisphosphonates or anabolic agents may be layered on or considered instead, but HRT remains a valuable tool for low bone density when started near menopause.
The cardiovascular story requires timing and route. Starting menopause hormone therapy before age 60 or within 10 years of the final period is associated with a more favorable cardiovascular profile compared with starting later. Transdermal estradiol appears to carry a lower risk of blood clots and stroke than oral estrogen at comparable doses, which matters in people with elevated baseline risk.
Cognition is more complicated. Estrogen started near menopause does not impair cognition and may help some people with word-finding or mental fog. Starting hormones after age 65 or long after menopause does not prevent dementia and can be harmful in certain settings. Here, the focus should be on symptom relief and quality of life, not dementia prevention.
For men on testosterone, sexual function and desire are the most consistent benefits. Lean mass increases and fat mass decreases modestly. Bone mineral density improves over time. Glycemic control may shift slightly in a favorable direction, but TRT is not a diabetes treatment. If fatigue and weight gain are the only issues, a careful search for other causes pays off.
Real risks, sized accurately
Any medical hormone therapy carries risks. The goal is to pick the lowest effective dose, the right delivery method, and the right length of therapy for the person in front of you.
For women with a uterus, unopposed estrogen grows the uterine lining and raises the risk of endometrial cancer. Adequate progesterone replacement therapy eliminates that excess risk. Micronized progesterone, 100 mg nightly continuously or 200 mg nightly for 12 to 14 days each month, is well tolerated by many. A levonorgestrel IUD can serve as endometrial protection in select cases, which can be useful if oral progesterone causes grogginess.
Combined estrogen and progestin therapy is associated with a small increase in breast cancer risk with longer use, especially beyond 3 to 5 years. The actual size of the risk depends on age, baseline risk, duration, and the specific progestogen. Estrogen alone in women without a uterus did not increase breast cancer risk in large trials and may reduce it slightly. Screening and risk assessment should be individualized, not decided by headlines.
Blood clots and stroke risks rise with oral estrogen in a dose-dependent fashion. Transdermal estradiol at standard doses has a lower clotting impact. Smoking, obesity, immobility, and inherited clotting disorders tilt the risk higher. If someone has a history of deep vein thrombosis, pulmonary embolism, stroke, or uncontrolled hypertension, transdermal routes and nonhormonal options deserve serious consideration.
Gallbladder disease, migraines, and elevated triglycerides can worsen with oral estrogen. Those side effects are less frequent with patches, gels, or sprays. Unscheduled bleeding during the first months is common, but persistent or heavy bleeding requires evaluation to rule out endometrial pathology.
For men, testosterone replacement can suppress sperm production and shrink testicular size. If fertility is a goal in the next year or two, avoid TRT and consider alternatives that stimulate the testes, such as clomiphene citrate or gonadotropins, under specialist care. Erythrocytosis, a rise in red blood cell mass, is a common dose-related side effect with injections and pellets and can increase clot risk; hematocrit must be monitored. Prostate-specific antigen rises modestly with TRT, and men with active prostate or breast cancer should not start therapy unless cleared by oncology and urology. Acne, fluid retention, mood shifts, and exacerbation of sleep apnea may occur.
Choosing the form and route
Oral estrogen is convenient and inexpensive, but it raises certain liver-mediated proteins and can aggravate clotting risk. Transdermal estradiol, delivered by patches, gels, or sprays, bypasses the liver’s first pass and tends to be safer for people with migraine, high triglycerides, higher body mass index, or a family history of clotting. Vaginal estrogen comes as tablets, rings, or creams, and because doses are tiny, systemic exposure is minimal. Local therapy is often the go-to for isolated genitourinary symptoms in someone who does not need or want whole-body hormone treatment.
Pellet hormone therapy involves subcutaneous implants of estradiol or testosterone. In my practice, pellets often produce supraphysiologic levels early and undertreatment later, are not easily reversible, and can create side effects that are harder to manage. For most, they are not the best first-line choice. Testosterone injections are effective and low cost but can cause peaks and troughs. Gels and patches give smoother levels but require daily application and precautions to avoid transfer to partners or children. A clinical hormone therapy program should lay out these trade-offs clearly, not funnel everyone toward one product.
Bioidentical, compounded, and custom: separating terms from reality
Bioidentical HRT means the molecule matches what the body makes. FDA-approved estradiol and micronized progesterone meet that standard and have the advantage of known potency and safety data. Compounded hormone therapy can be helpful when someone needs a form or dose that does not exist commercially, or when they have intolerances to excipients. But routine use of compounded creams or lozenges simply because they are called natural hormone therapy is not safer or more effective than approved options. Salivary hormone testing is heavily marketed yet does not reliably guide dosing. Blood levels have a role, but symptom tracking and side effect monitoring carry more weight in day-to-day adjustments.
Who should consider a conversation now
- Women with moderate to severe hot flashes, night sweats, sleep disruption, or vaginal dryness that limits sex or daily life Anyone with premature ovarian insufficiency or surgical menopause at a young age Postmenopausal people with low bone density who are within 10 years of their final period Men with symptoms of low testosterone and at least two separate morning labs showing low total testosterone People who tried nonhormonal strategies without adequate relief and want to understand the benefits and risks of hormone treatment
What a sound evaluation looks like
A thoughtful hormone therapy consultation starts with a timeline of symptoms and menstrual history, a medication review, and a targeted exam. If monthly cycles are still occurring, documenting the pattern helps distinguish perimenopause from other issues like thyroid disease, anemia, or depression. A baseline blood pressure and body mass index give context, because both affect risk.
Lab testing is often straightforward. In classic menopause, lab confirmation is unnecessary. If periods are erratic and someone is younger than expected, checking follicle-stimulating hormone, estradiol, and thyroid function helps. For TRT, guidelines still recommend at least two separate morning total testosterone levels, measured by a reliable assay, in the context of symptoms. Sex hormone binding globulin or free testosterone may add clarity if levels sit near the cutoff. For thyroid hormone therapy, a TSH and free T4 define the baseline; T3 levels are not the main driver for starting or adjusting levothyroxine in most cases.
Cancer screening status should be current according to age and risk. Unexplained vaginal bleeding needs evaluation before starting estrogen. In men, a baseline hematocrit and PSA, paired with a focused prostate assessment, set the stage for safe monitoring.
Dosing and the art of “just enough”
For menopause HRT, I often start with a low-dose transdermal estradiol patch, for example 0.025 mg per day, and titrate every 2 to 4 weeks until symptoms settle. If someone is sensitive to medications or has migraine with aura, smaller steps can help. Micronized progesterone at bedtime can improve sleep architecture on its own, and many patients feel the difference in a week. If continuous progesterone causes grogginess, cyclic dosing or switching to a different progestogen can solve it. Vaginal estradiol at low doses can be used indefinitely for local symptoms, often without the need for systemic progestogen because the dose is so small.
For TRT, the target is a mid-normal serum testosterone level matched to time of dosing and route. With weekly injections, labs should be drawn midway between injections to avoid peak bias. With gels, check levels 2 to 4 hours after application. Symptoms should improve alongside numbers. Overshooting brings risk without extra benefit.
Monitoring and follow-up that protects you
- Revisit at 6 to 12 weeks to assess symptom relief, side effects, and check blood pressure. Adjust dose based on lived experience, not just labs. For women on systemic HRT, continue age-appropriate breast screening and keep cervical screening current. Any new bleeding warrants prompt evaluation. For men on TRT, recheck testosterone, hematocrit, and PSA at about 3 months, then every 6 to 12 months. If hematocrit climbs above the safe range, lower the dose or switch route. Review cardiovascular risk factors yearly. If routes can be optimized to reduce risk, switch early rather than late. Every year, revisit whether therapy still serves your goals. Some continue for years, others taper after symptoms subside.
Special situations that change the plan
Migraine with aura raises baseline stroke risk. In that setting, transdermal estradiol is preferred over oral, and the lowest effective dose should be used. Smokers and people with obesity face higher clot risk with oral estrogen. Diabetes and high triglycerides point toward patches or gels. A history of endometriosis can flare on estrogen alone after hysterectomy, and add-back progesterone or alternative strategies can limit recurrence. After breast cancer, any hormone therapy discussion must be coordinated with oncology; local vaginal estrogen may still be acceptable for severe symptoms in some cases.
People with premature ovarian insufficiency need replacement-strength estrogen and progesterone, not the tiny doses used for symptom control late in menopause. The agenda is long-term bone and organ protection as much as symptom relief. Here, a robust dose and steady adherence matter.
What about testosterone in women
Low libido is common, and hormones are only one piece. Transdermal testosterone at very low doses can help postmenopausal women with diagnosed hypoactive sexual desire disorder, when nonhormonal contributors are addressed. In the United States this is off-label, and careful dosing is essential to avoid side effects like acne, hair loss at the temples, and voice changes. Pellets often overshoot and carry a higher risk of side effects. If a clinic markets testosterone to all women as anti aging hormone therapy or hormone rejuvenation therapy, be cautious. The goal is to restore physiologic levels, not to chase supraphysiologic numbers.
Thyroid hormone therapy belongs in its lane
Thyroid hormone replacement, most often levothyroxine, treats hypothyroidism. It is highly effective when indicated and harmful if overused. Fatigue, weight gain, and low mood do not automatically mean low thyroid. Before adjusting thyroid hormones in a hormone optimization therapy program, confirm the diagnosis with a clear TSH and free T4 pattern. Combination T4 and T3 therapy can help a subset of patients, but it requires tight monitoring to avoid palpitations, bone loss, and anxiety.
Cost, access, and how to spot quality care
Costs vary by route and brand. Generic estradiol patches and micronized progesterone are widely covered and affordable for many. Gels and sprays can be pricier. Local vaginal estrogen often runs a few dollars per week. TRT injections are inexpensive, while gels and patches cost more and sometimes require prior authorization. Pellet procedures frequently cost hundreds to over a thousand dollars per insertion and are usually cash pay.
A good hormone therapy clinic lays out options and costs transparently, explains risks and benefits without minimizing either, and monitors you at rational intervals. Red flags include promises to cure every problem with a single protocol, routine use of compounded high-dose hormones when approved options exist, and heavy reliance on salivary testing to dictate dosing. Personalized hormone therapy is about matching your history and preferences to evidence-based options, not about inventing numbers to chase.
When HRT is not the right tool
Some people should avoid systemic estrogen, at least for a time. Absolute contraindications include active or recent hormone-sensitive cancer, unexplained vaginal bleeding, active liver disease, and a recent clot or stroke not fully evaluated. In those cases, effective nonhormonal options exist for hot flashes, including certain antidepressants, gabapentin, oxybutynin, and the newer neurokinin 3 receptor antagonist class. For genitourinary symptoms, local therapies and pelvic floor support can go a long way.
For men, TRT should not be started if fertility is desired soon, if hematocrit is already high, or if there is untreated severe sleep apnea or active prostate cancer. Many men with fatigue and low mood improve more with sleep optimization, treatment of apnea, resistance training, alcohol moderation, and addressing depression or anxiety than with testosterone.
A practical path to getting started
Begin with a clear goal. Are you aiming to sleep through the night, stop changing soaked pajamas, enjoy sex without pain, or stop worrying about bone loss? Put those targets on paper. Choose a starting dose with a plan for how you will judge success in 6 to 8 weeks. Keep a brief symptom diary; it beats memory when fine-tuning. If you run into side effects, tell your clinician quickly. Most have a workaround, whether switching from oral to transdermal, changing a progestogen, or splitting a dose.
Expect a fair discussion about duration. Many women use systemic HRT for several years until symptoms fade, then taper. Some continue longer because benefits clearly outweigh risks for them. Others prefer local estrogen only. There is no one-size rule. In men, expect a longer horizon if the cause of low testosterone is permanent, paired with steady monitoring.
The teacher I mentioned earlier stayed on a low-dose patch and nightly progesterone for three years. When we tapered, the hot flashes did not return, and she stayed on local vaginal estrogen. Bone density, checked along the way, hormone therapy near me stayed stable. That is boring medicine in the best sense, the kind that gives someone their life back without fanfare.
The core message is simple: hormone therapy can be safe hormone therapy when matched to the right person with the right preparation. Anchor decisions in symptoms, timing, and personal risk. Favor routes and doses that respect physiology. Be skeptical of grand promises and one-size answers. When hormone therapy specialists listen first and prescribe second, the balance of benefits to risks often looks very good.